Objective: Drugs that enhance cholinergic transmission have demonstrated promise treating addictive disorders. Galantamine, an acetylcholinesterase inhibitor, may reduce cigarette smoking in otherwise healthy treatment-seeking smokers.
together, galantamine may be an effective pharmacological aid for the treatment of TUD, but its effects on smoking behavior and broader outcomes (e.g., cognitive function) in laboratory and natural settings remain unexamined.
We conducted a double-blind, placebo-controlled study that randomized daily smokers to receive galantamine extended release (8 or 16 mg/day), or placebo for 7 weeks. Our goals were to evaluate recent findings (i.e., Ashare et al., 2016) in an inclusive population of healthy smokers using laboratory and field-based assessments (ecological momentary assessment [EMA] ). To evaluate the effects of galantamine in the absence of other interventions during ad-lib smoking, we evaluated behavior prior to a quit attempt (e.g., Weeks 1-4). Participation in the post-quit portion of the study was optional (see Supporting Information). We hypothesized that, compared with placebo, galantamine would reduce smoking behavior and decisions to smoke in a smoking choice task. Regarding its mechanism of action, we predicted that galantamine would attenuate subjective satisfaction/pleasure from smoking and improve performance on cognitive tasks measured in the laboratory and the field.
| METHOD

| Participants
A total of 60 participants were enrolled and randomized ( Figure 1 ).
The overall sample was 62% male, predominantly Caucasian (77%), with a mean age of 38.3 years (SD = 10.0), and reported smoking an average of 13.7 (SD = 6.9) cpd. Treatment groups did not differ by any characteristics measured (p's > 0.12), except cpd (p = 0.03). Post hoc comparisons revealed a significant difference between the 8-and 16-mg groups (p = 0.02); all comparisons with placebo were not significant (p's > 0.28). The Human Subjects Subcommittee at the VA Connecticut Healthcare System and Institutional Review Board at Yale University approved all study procedures.
| Treatment and study protocol
After a baseline visit, the study contained two phases: Phase 1 (prequit; Weeks 1-4) and Phase 2 (post-quit; Weeks 5-7). Outline of study protocol can be found in Figure 2 . The current manuscript evaluates the effect of galantamine on ad-lib smoking behavior prior to a quit attempt (i.e., Phase 1). For laboratory-based assessments, participants attended twice-weekly visits to complete measures on self-reported nicotine effects, normal smoking behavior, and smoking choice task after 12 hr of abstinence (Tidey, O'Neill, & Higgins, 2000) during Week 3. Participants also completed an EMA paradigm on Week 4. For EMA paradigm, participants were given a personal digital assistant that signaled four assessments at random times each day (random assessments) and permitted user-initiated assessments. Laboratory visits included assessments for smoking satisfaction and pleasure from cigarettes over the past week (1 = not at all, 7 = extremely), breath CO (Vitalograph, Lenexa, KS), urine cotinine, and 7-day substance use calendar. Urine cotinine was positively correlated with mean selfreport cigarettes smoked in the same week (r = 0.34, p < 0.001).
EMA surveys included real-time reports of smoking behavior and items assessing smoking satisfaction (1 = not at all, 7 = extremely) and pleasure (1 = not at all, 7 = extremely) for the last cigarette smoked.
All participants completed the Go/No-go task (Sofuoglu, Waters, Mooney, & Kosten, 2008 ) and a Rapid Visual Information Processing (RVIP) task (Foulds et al., 1996) at baseline and throughout study during laboratory-based visits and EMA. For the laboratory-based and EMA Go/No-go tasks, 225 numbers (range = 1-9) were presented for 250 ms followed by a 900-ms mask (i.e., one letter every 1,150 ms). Participants were instructed to press the response button FIGURE 1 CONSORT flow diagram. Missing data: a = technical error, b = participant error, c did not complete ecological momentary assessment (EMA) surveys. Numbers reflect number of cases (e.g., b2 = data from two participants were lost due to participant error). cpd: cigarettes per day; RVIP: Rapid Visual Information Processing for every number except "3." The primary measures on the Go/No-go task were number of commission errors on the no response target (i.e., responding to the number "3"). Other performance measures included number of omission errors (i.e., not responding to numbers other than "3") and average response reaction time. Reaction times less than 100 ms were discarded from analysis. For the laboratory RVIP task, a series of single digits were presented at a rate of 100 digits per minute. Participants were instructed to detect a three target sequences ("2-4-6," "3-5-7," and "4-6-8") and press the space bar within 1,800 ms of the last target being displayed. To reduce the impact of practice effects after repeated administration during EMA, targets were defined as three consecutive odd digits (e.g., 7-9-3) or three consecutive even digits (e.g., 2-8-6). Participants were instructed to press the response button as quickly as possible after detecting a target. For both the laboratory and EMA tasks, a total of 32 targets were presented (eight targets per minute) with 5 to 30 digits between each target. Performance measures on the RVIP were the percentage of targets correctly detected (i.e., hits), average response latency, and number of false positives. During EMA, the personal digital assistant was programmed to administer either the Go/No-go task or the RVIP task (in an alternating sequence) using the same parameters as laboratory versions.
| Data reduction and analytic plan
For RVIP performance, data from Phase 1 EMA (i.e., Week 4) were excluded for the following reasons. Data from one assessment (0.31% of 327 total assessments) were excluded due to experimenter error in set up of sequences (excessive number of trials). Data from 108 assessments (33.18% of 326 assessments) were excluded due to no responses (either hits or false alarms) during the task, indicating that the participant was likely not attempting to complete the task appropriately. Of the remaining 218 assessments, data from 22 assessments (10.09% of 218 assessments) were excluded due to an excessive number (>100) of false alarms, indicating that participants were pressing the response button repeatedly. After these exclusions, 37 of the 39 participants (94.87%) provided RVIP data 16 mg GAL (n = 14; 8 mg GAL (n = 14); placebo (n = 9).
For Go/No-go performance, data from Phase 1 EMA were excluded for the following reasons. Data from 16 assessments (5.02% of the total 319 Go/No-go assessments) were excluded due to experimenter error in set up of sequences (e.g., excessive number of trials or incorrect sequences). Data from 71 assessments (23.43% of 303) were excluded due to an excessive number (>100 out of 200) of errors on Go trials (failing to press a button for a non-3), indicating that participants were not performing the task appropriately.
After these exclusions, 32 of the 39 participants (82.05%) provided Go/No-go data 16 mg GAL (n = 11); 8 mg GAL (n = 14); placebo (n = 7).
Linear mixed models (LMM; SAS Systems, Cary, NC) tested the effect of Treatment on outcomes including measures of cognitive performance (RVIP and Go/No-go), smoking behavior (self-administration in smoking choice task, self-reported cpd, and urine cotinine), and subjective effects from smoking (i.e., satisfaction and pleasure). For Compliance with medication via pill count was excellent at 96.8%.
Summary statistics for all smoking behavior are in Table 1 and cognitive performance in Table 2 . All models were rerun with cpd entered as a covariate, and results were unchanged (Table S1 ).
3 | RESULTS
| Smoking behavior
LMMs conducted on laboratory data revealed a significant effect of Treatment on urine cotinine, reflecting a reduction in urine cotinine in both galantamine groups compared with placebo (Table 3) LMMs on EMA field data revealed no significant effects of Treatment.
| Cognitive performance
LMMs of laboratory data revealed an effect of Time such that participants improved performance on the RVIP task irrespective of Treatment. Analysis of EMA data revealed that galantamine administration was associated with decreased latency to respond on the RVIP task. All other main effects and Treatment × Time interactions were nonsignificant (Table 3) .
| DISCUSSION
In this pilot study, galantamine, compared with placebo, reduced selfadministration in a smoking choice task and reduced urine cotinine levels during the pre-quit period. Notably, galantamine did not affect self-reported cpd, smoking satisfaction/pleasure, or cognitive performance in the laboratory or the field. These findings partially support those of Ashare et al. that reported galantamine reduced smoking behavior (i.e., cotinine); in contrast, we did not detect decreased cpd or satisfaction/pleasure from smoking associated with galantamine administration in either laboratory or EMA data. It is possible that the inclusion of lighter smokers (i.e., >5 cpd) may reduce power to detect smaller decreases in cpd. However, the observed decrease in cotinine in both galantamine groups is strengthened by prior research suggesting that biochemical confirmation of smoking confirmed using cotinine is more reliable than self-report (Connor Gorber, Schofield- Although the exact neural mechanism is unknown, galantamine is believed to reduce smoking behavior via positive allostatic modulation Anchors for smoking satisfaction and pleasure scale for lab and field data were 1 = not at all and 7 = extremely. Outcome measure for smoking choice task was the number of times an individual chose to smoke (vs.
abstain to earn money). of α4β2 nAChRs in the brain. Preclinical studies have established the role of α4β2 nAChRs in nicotine reinforcement (Maskos et al., 2005; Tapper et al., 2004) , and drugs that target α4β2 nAChRs, such as varenicline, are associated with decreased nicotine intake in rodents (George, Lloyd, Carroll, Damaj, & Koob, 2011) and increased smoking cessation in humans (Gonzales et al., 2006) . Like varenicline, galantamine is assumed to reduce the subjective effects of acute nicotine exposure thereby decreasing satisfaction and reward from smoking;
however, this study did not find any significant effects of galantamine on subjective effects from smoking. Galantamine's capacity to attenuate the reinforcing effects of nicotine may be more evident after acute nicotine exposure, as observed in preclinical and clinical laboratory studies (Hopkins, Rupprecht, Hayes, Blendy, & Schmidt, 2012; Sofuoglu, Herman, Li, & Waters, 2012) . Additionally, cognitive performance was not significantly affected by galantamine administration in the laboratory or during EMA.
By repeatedly assessing cognitive performance in both the laboratory and daily life, we intended to evaluate enhanced cognitive performance as a possible mechanism for reduced smoking or agonist-like effects of galantamine. Indeed, galantamine has been associated with increased cognitive performance in individuals with baseline cognitive deficits such as Alzheimer's disease (Takeda et al., 2006) , schizophrenia Schubert, Young, & Hicks, 2006) , and cocaine use disorder (Sofuoglu, Waters, Poling, & Carroll, 2011) ; but studies failing to replicate cognitive improvements should be noted (Buchanan et al., 2017; Raina et al., 2008) . The efficacy for cognitive enhancement as a treatment for drug addictions is still developing (Sofuoglu, DeVito, Waters, & Carroll, 2013) . Preclinical studies have also suggested that other positive allosteric modulators of α4β2 nAChRs that do not inhibit acetylcholinesterase reduce nicotine self-administration (Hamouda, Jackson, Bagdas, & Damaj, 2017; Maurer, Sandager-Nielsen, & Schmidt, 2017) and improve cognitive performance (Pandya & Yakel, 2013) . The efficacy of these compounds in reducing smoking behavior and enhancing cognition in treatment-seeking smokers may be greater than galantamine and is an important direction for future studies.
| CONCLUSION
Study limitations include the small sample size, meaning that the study only had good power to detect large effect sizes, and the inclusion of 
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